Onesource Specialty Pharma Limited · NSE:ONESOURCE
Onesource Specialty Pharma — Q2 FY26 Earnings Presentation
23 slides from Onesource Specialty Pharma's earnings presentation, Nov 12, 2025
Slide 1: Exchange filing cover letter
Corporate Office: Registered Office: Star 1, Opp IIM Bangalore, Bilekahalli, Cyber One, Unit No. 902, Sector 30A Bannergha a Road, Bengaluru – Plot No - 4 & 6, Vashi, Navi Mumbai 560076, India 400703 India T: +91 80 6784 0738 F: +91 22 2789 2924 T: 91 22 2789 2942 Date: November 12, 2025 BSE Limited Nat
Slide 2: Investor Presentation | Q2FY26
Investor Presentation | Q2FY26 November 12th, 2025
Slide 3: Safe Harbor Statement
Safe Harbor Statement Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "i
Slide 4: Financial Performance
Financial Performance ONe€SOUurICe
Slide 5: Q2FY26 Performance Snapshot
Q2FY26 performance in line with year-on-year revenue growth and margin expansion ( Q2FY26 Performance Snapshot ) ₹3,758m Revenue Q2 performance was underpinned by MSAs executions and sales from our IP led base business. DDC capacity $43.1m 12% YoY addition is being accelerated to support upcoming cu
Slide 6: Q2FY26 financial performance highlights sustained YoY growth and profitability
Q2FY26 financial performance highlights sustained YoY growth and profitability In $ m Q2FY26 Q1FY26 Q2FY25 YoY Key Updates Revenue 43.1 37.6 38.3 12% • Revenue: Q2 revenue stood at $43.1 m / EBITDA 12.2 10.2 8.9 37% ₹3,758 m, an increase of 12% YoY, driven by execution of MSAs EBITDA margin (%) 28%
Slide 7: Recently proposed acquisition strengthens the H1FY26 performance of OneSource
Recently proposed acquisition strengthens the H1FY26 performance of OneSource H1FY26 Performance + Proforma + Proforma = Proforma Combined Revenue 81 ~21 ~8 ~110 ($m) EBITDA ($m) 22 ~7 ~4 ~33 EBITDA margin % 28% 32% 46% 30% As of 30 September 2025, net debt for the incoming business stands at $11.5m
Slide 8: Business & Operational Updates
Business & Operational Updates
Slide 9: Strong momentum continues in drug-device-combinations and base business
Strong momentum continues in drug-device-combinations (DDCs) and base business of soft gel capsules and injectables Scaling up DDC capacities Deepening the base business • Commercial forecasts continue to trend upward across key • Signed 9 new MSAs and licensing agreements across markets — Canada, B
Slide 10: Further expanded end-to-end capability in DDCs by onboarding new device platforms
Further expanded end-to-end capability in DDCs by onboarding new device platforms Added in Q2 PFS with/ with- Dial & push Variable dose Dial & push Variable & Fixed Dial & push Fixed Pull push Fixed Autoinjectors out Safety Pen injectors dose Pen injectors dose Pen injectors Dose Pen Device 8
Slide 11: DDC capacity expansion in full swing at our flagship site
DDC capacity expansion in full swing at our flagship site to support upcoming commercial supplies Flagship facility expansion: Significant on-site progress Capacity (in millions) Current Planned Cartridges 40 ~220 Pre-filled Syringes 38 ~50 9
Slide 12: Significant boost to biologics funnel on customer outreach and industry tailwinds
Significant boost to biologics funnel on the back of customer outreach and highly supportive industry tailwinds Strong customer outreach Industry tailwinds • Easing regulatory pathways for biosimilar development by • Strengthened sales and marketing team in US with industry US FDA to bring down cost
Slide 13: Progressing towards stronger governance with integrated reporting and improved disclosure practices
Progressing towards stronger governance with integrated reporting and improved disclosure practices • Inaugural Integrated Report (FY25) – A key milestone in our journey towards greater transparency, accountability, and sustainable value creation • Voluntarily adopted BRSR in FY25 • United Nations G
Slide 14: Acquisition Progress
Acquisition Progress ONe€SOUurICe
Slide 15: Building global footprint through acquisition of European CDMO and Indian anti-infective businesses
Building global footprint and expanding capabilities through acquisition of European CDMO and Indian anti-infective businesses Scale • EU based sterile fill finish USFDA approved site with multiple dose formats, long term CDMO contract signed to manufacture the largest anaesthetic brand in Europe •
Slide 16: Comprehensive regulatory process including NCLT and shareholder approvals
Comprehensive regulatory process including NCLT and shareholder approvals with closure expected by December 2026 The Independent sub-committee (Dr. Claudio Albrecht, Colin Michael Bond and Vijay Karwal) was constituted to review the proposed Scheme Effective, fixing Record Date and Issuance of Share
Slide 17: Business Outlook
Business Outlook ONe€SOUurICe
Slide 18: Upward revision of FY28 financial outlook
Upward revision of FY28 financial outlook Organic Growth Outlook • Already committed 65% of ~$100m capex planned for capacity expansion In $m FY28 • Accelerating Phase 2 of capacity expansion to be operational a year ahead of the schedule Revenue 400 • Major upgrade underway in one of the injectable
Slide 19: Q2FY26 earnings call schedule
Q2FY26 Nov Day: Wednesday 12 Schedule: Date: 12th November 2025 Time: 3:00 PM IST Arun Kumar, Founder & Non-Executive Chairperson Speakers: Neeraj Sharma, CEO & MD Anurag Bhagania, CFO +91 22 6280 1372 Dial In: +91 22 7115 8193 Diamond Pass: Click here for early registration
Slide 20: OneSource at a Glance
OneSource at a Glance
Slide 21: Building first-of-its-kind CDMO platform
Building first-of-its-kind CDMO platform, distinguished by extensive capabilities and robust financial metrics ROBUST MANUFACTURING & PRESENCE ACROSS HIGHLY ATTRACTIVE EXPERT PROFESSIONALS AND ONE-OF-ITS-KIND COMPLIANCE TRACK RECORD MODALITIES INCLUDING GLP-1 FINANCIAL PROFILE SEASONED BOARD #1 5 Mu
Slide 22: Industry-leading capacities backed by stellar compliance record
Industry-leading capacities backed by stellar compliance record Drug-device combinations Biologics development centre Sterile Injectables Soft gelatin capsules1 Penicillin fill-finish Integrated Biologics and Drug Products site Area (Sq ft) 450,000 100,000 70,000 60,000 42,000 Microbial: 1x1KL SS Ca
Slide 23: Get in touch with us
Get in touch with us REGISTERED AND CORPORATE OFFICE INVESTOR RELATIONS OneSource Specialty Pharma Ltd Investor-relations@onesourcecdmo.com Investor-relations@onesourcecdmo.com Registered Office: Unit No. 902, Cyber One, Plot No - 4 & 6, Sector 30A, Vashi, Navi Mumbai, Sanpada, Thane, Maharashtra, I
OneSource Specialty Pharma — Q2 FY26 Earnings Presentation on 6ix